Ioannis Zerdes

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS. 2024;28(9):5312-5322
Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images
Tsiknakis N; Manikis G; Tzoras E; Salgkamis D; Vidal JM; Wang K; Zaridis D; Sifakis E; Zerdes I; Bergh J; Hartman J; Acs B; Marias K; Foukakis T
Article: NATURE COMMUNICATIONS. 2024;15(1):3837
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Wang K; Zerdes I; Johansson HJ; Sarhan D; Sun Y; Kanellis DC; Sifakis EG; Mezheyeuski A; Liu X; Loman N; Hedenfalk I; Bergh J; Bartek J; Hatschek T; Lehtio J; Matikas A; Foukakis T
Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(2):299-308
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
Article: ESMO OPEN. 2023;8(6):102069
Validation of the ALK-Brain Prognostic Index for patients with ALK- rearranged lung cancer and brain metastases
Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
Article: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2023;2023:1-4
Multiresolution Self-Supervised Feature Integration via Attention Multiple Instance Learning for Histopathology Analysis.
Tsiknakis N; Tzoras E; Zerdes I; Manikis GC; Acs B; Hartman J; Hatschek T; Foukakis T; Marias K
Article: CLINICAL CANCER RESEARCH. 2023;29(3):532-540
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Gryback P; Bjohle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Article: NPJ BREAST CANCER. 2021;7(1):144
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Article: CANCERS. 2021;13(18):4655
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Ruiz PM; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Article: JAMA ONCOLOGY. 2021;7(9):1360-1367
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial
Hatschek T; Foukakis T; Bjohle J; Lekberg T; Fredholm H; Elinder E; Bosch A; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Azavedo E; Gryback P; Hellstrom M; Johansson H; Maes C; Zerdes I; Hartman J; Brandberg Y; Bergh J
Article: ESMO OPEN. 2021;6(2):100076
bPrognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjohle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellstrom M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
Article: ESMO OPEN. 2020;5(6):e001032
PD-1 protein and gene expression as prognostic factors in early breast cancer
Matikas A; Zerdes I; Lovrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Zerdes I; Sifakis EG; Matikas A; Chretien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Article: CELL DEATH AND DISEASE. 2020;11(1):69
SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12
Gonzalez-Rodriguez P; Engskog-Vlachos P; Zhang H; Murgoci A-N; Zerdes I; Joseph B
Article: CANCERS. 2019;11(10):E1479-1479
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Zerdes I; Wallerius M; Sifakis EG; Wallmann T; Betts S; Bartish M; Tsesmetzis N; Tobin NP; Coucoravas C; Bergh J; Rassidakis GZ; Rolny C; Foukakis T
Journal article: FORUM OF CLINICAL ONCOLOGY. 2018;9(1):17-29
The outcome-based iCAN! / theyCAN! feedback paradigm differentiates strong and weak learning outcomes, learner diversity, and the learning outcomes of each learner: A shift to metacognitive assessment
Dimoliatis IDK; Zerdes I; Zampeta A; Tziortzioti Z; Briasoulis E; Souglakos I
Article: HEMATOLOGY REPORTS. 2018;10(1):7070
Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature.
Boussios S; Zerdes I; Vassou A; Bareta E; Seraj E; Papoudou-Bai A; Pavlidis N; Batistatou A; Pentheroudakis G
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Article: JOURNAL OF B.U.ON.. 2017;22(5):1240-1245
Addressing the post-irradiation hypothalamic-pituitary endocrine abnormalities of brain tumors in pediatric patients
Velentza L; Tolia M; Christakou C; Nikolaou M; Zerdes I; Tsoukalas N; Hajiioannou J; Tsanadis K; Rigas G; Mitsis M; Theodorou K; Pistevou-Gombaki K; Tsekeris P; Kyrgias G
Article: JOURNAL OF B.U.ON.. 2017;22(4):1073-1080
How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options.
Zerdes I; Tolia M; Nikolaou M; Tsoukalas N; Velentza L; Hajiioannou J; Mitsis M; Kyrgias G
Journal article: CASE REPORTS IN HEMATOLOGY. 2017;2017:2861596-5
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review.
Hatzimichael E; Papathanasiou K; Zerdes I; Flindris S; Papoudou-Bai A; Kapsali E
Article: INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS. 2016;27:198-201
Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence.
Boussios S; Zerdes I; Batsi O; Papakostas VP; Seraj E; Pentheroudakis G; Glantzounis GK
Article: DIGESTIVE DISEASES AND SCIENCES. 2016;61(1):273-282
Sense of Coherence and Defense Style Predict Sleep Difficulties in Early Non-metastatic Colorectal Cancer.
Hyphantis T; Goulia P; Zerdes I; Solomou S; Andreoulakis E; Carvalho AF; Pavlidis N
Visa fler

Alla övriga publikationer

Conference publication: CANCER RESEARCH. 2024;84(9):po2-07-06-po2-07-06
Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Sifakis E; Manikis G; Salgkamis D; Tsiknakis N; Harbers L; Crosetto N; Bergh J; Matikas A; Hatschek T; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103031
23P Longitudinal evaluation of PAM50 molecular subtypes in patients receiving neoadjuvant HER2-targeted therapy in the PREDIX HER2 trial
Zhu Y; Sifakis EG; Wang K; Zerdes I; Bergh J; Hatschek T; Matikas A; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103110
122P Primary results and biomarker analysis from PREDIX LumB: A prospective randomized phase II trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer
Matikas A; Bjöhle J; Barnekow E; Isakssonfriman E; Zouzos A; Tzoras E; Johansson H; Margolin S; Acs B; Boyaci C; Sun W; Zerdes I; Kessler LE; Grybäck P; Hellström M; Hartman J; Brandberg Y; Bergh J; Hatschek T; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103063
56P Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: A secondary analysis of the phase II PREDIX HER2 trial
Zerdes I; Wang K; Salgkamis D; Zhu Y; Sifakis EG; Acs B; Hartman J; Hatschek T; Bergh J; Matikas A; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103075
69P Deep learning prognostication through prediction of TP53 gene mutation status on breast cancer hematoxylin and eosin slides
Tsiknakis N; Salgkamis D; Tzoras E; Wang K; Liu X; Manikis G; Sifakis EG; Bergh J; Marias K; Zerdes I; Matikas A; Foukakis T
Conference publication: EUROPEAN JOURNAL OF CANCER. 2024;200:113830
Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer
Foukakis T; Wang K; Zerdes I; Zhu Y; Sifakis E; Tsiknakis N; Manikis G; Salgkamis D; Harbers L; Bergh J; Johansson H; Crosetto N; Lehtio J; Matikas A; Hatschek T
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2023;192:104189
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s599
EP09.04-01 Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases
Tsakonas G; Skribek M; Kamali C; Zerdes I; Jóhannsdóttir B; Ekman S
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):s647
EP12.01-18 Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases
Tsakonas G; Kamali C; Zerdes I; Koulouris A; Hydbring P; Christopoulos P
Meeting abstract: ANNALS OF ONCOLOGY. 2023;34:s307-s308
Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up
Zerdes I; Matikas A; Mezheyeuski A; Acs B; Johansson H; Manikis G; Boyaci C; Boman CE; Poncet C; Ignatiadis M; Bai Y; Rimm D; MacGrogan G; Cameron DA; Bergh J; Bonnefoi H; Foukakis T
Meeting abstract: ANNALS OF ONCOLOGY. 2023;34:s925
Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group
Pellat A; Grinda T; Prelaj A; Cresta P; Valachis A; Zerdes I; Branco DM; Provenzano L; Spagnoletti A; Marta GN; Wilson B; Montemurro F; Castelo-Branco L; Pentheroudakis G; Delaloge S; Koopman M
Review: BREAST CANCER RESEARCH AND TREATMENT. 2023;201(2):161-169
Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
Rosin J; Svegrup E; Valachis A; Zerdes I
Editorial comment: MOLECULAR ONCOLOGY. 2023;17(4):545-547
The interplay between eosinophils and T cells in breast cancer immunotherapy
Zerdes I; Matikas A; Foukakis T
Meeting abstract: CANCER RESEARCH. 2023;83(5):p2-21-02-p2-21-02
Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial
Zerdes I; Salgkamis D; Matikas A; Selander L; Wang K; Tzoras E; Sifakis E; Agartz S; Chen X; Hellstrom M; Hartman J; Bergh J; Foukakis T; Hatschek T
Meeting abstract: CANCER RESEARCH. 2023;83(5):p5-02-20-p5-02-20
Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Matikas A; Sifakis E; Salgkamis D; Bjohle J; Elinder E; Margolin S; Campos AB; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Johansson H; Hellstrom M; Azavedo E; Hartman J; Bergh J; Hatschek T; Foukakis T
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):S647
Validation of the ALK-Brain Prognostic Index (ALKBPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases
Tsakonas G; Kamali C; Zerdes I; Koulouris A; Hydbring P; Christopoulos P
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2023;18(11):S599
Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases
Tsakonas G; Skribek M; Kamali C; Zerdes I; Johannsdottir B; Ekman S
Conference publication: CANCER RESEARCH. 2022;82(12_Supplement):2045
Abstract 2045: Spatial organization of the immune microenvironment after neoadjuvant treatment of breast cancer
Thomas N; Garaud S; Langouo M; Zerdes I; Sofronii D; Boisson A; Foukakis T; De Wind A; Salgado R; Awada A; Willard-Gallo K
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12598
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12620
Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.
Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):593
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
Matikas A; Johansson H; Grybäck P; Bjöhle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33:S125
Longitudinal proteogenomic profiling reveals therapeutic vulnerabilities of immunometabolism in breast cancer
Wang K; Zerdes I; Sifakis EG; Johansson HJ; Mezheyeuski A; Lehtio J; Bergh J; Hatschek T; Matikas A; Foukakis T
Review: CANCERS. 2022;14(8):1999
Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
Tzoras E; Zerdes I; Tsiknakis N; Manikis GC; Mezheyeuski A; Bergh J; Matikas A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
Conference publication: CANCER RESEARCH. 2022;82(12)
Spatial organization of the immune microenvironment after neoadjuvant treatment of breast cancer
Thomas N; Garaud S; Langouo M; Zerdes I; Sofronii D; Boisson A; Foukakis T; De Wind A; Salgado R; Awada A; Willard-Gallo K
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.
Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
Matikas A; Johansson H; Gryback P; Bjohle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
Review: FRONTIERS IN ONCOLOGY. 2022;12:999843
Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
Zhu Y; Tzoras E; Matikas A; Bergh J; Valachis A; Zerdes I; Foukakis T
Review: CANCER TREATMENT REVIEWS. 2021;99:102257
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Boman C; Zerdes I; Martensson K; Bergh J; Foukakis T; Valachis A; Matikas A
Conference publication: CANCER RESEARCH. 2021;81(4_Supplement):ps18-27-ps18-27
Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Conference publication: CANCER RESEARCH. 2021;81(4)
Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S328
Heterogeneity of PD-L1 expression at the protein and mRNA levels in early breast cancer
Zerdes I; Stogiannitsi M; Bergh J; Hatschek T; Foukakis T; Matikas A
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):545
PD-1 protein and gene expression in early breast cancer: Prognostic implications.
Zerdes I; Matikas A; Lövrot J; Sifakis EG; Richard F; Sotiriou C; Rassidakis GZ; Bergh JCS; Valachis A; Foukakis T
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S49
PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels
Hatschek T; Andersson A; Bjohle J; Bosch A; Carlsson L; Dreifaldt AC; Einbeigi Z; Elinder E; Fredholm H; Isaksson-Friman E; Hellstrom M; Johansson H; Lekberg T; Lindman H; Zerdes I; Foukakis T; Hartman J; Brandberg Y; Bergh J
Thesis / dissertation: 2020
Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer : biology and clinical implications
Zerdes, Ioannis
Meeting abstract: CANCER RESEARCH. 2020;80(4):p3-08-07-p3-08-07
Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer
Kouvaraki M; Sifakis EG; Zerdes I; Herold N; Bergh J; Rassidakis GZ; Foukakis T
Review: CLINICAL CANCER RESEARCH. 2019;25(18):5717-5726
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):550
Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2-early breast cancer.
Zerdes I; Sifakis EG; Tobin N; Bergh JCS; Matikas A; Foukakis T
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):e14284
Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh JCS; Valachis A; Foukakis T
Review: CANCERS. 2019;11(5):E628-628
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chretien S; Zerdes I; Bergh J; Matikas A; Foukakis T
Meeting abstract: CANCER RESEARCH. 2019;79(4):p2-08-25-p2-08-25
PD-L1 expression at the protein and RNA levels as prognostic factor in early breast cancer
Zerdes I; Sifakis E; Matikas A; Tobin NP; Charlotte R; Rassidakis GZ; Bergh J; Foukakis T
Review: UROLOGIA JOURNAL. 2019;86(1):3-8
Systemic therapy of metastatic renal cell carcinoma: Review of the current literature.
Zerdes I; Tolia M; Tsoukalas N; Mitsis M; Kardamakis D; Pistevou-Gombaki K; Tsekeris P; Kyrgias G
Book chapter: INTERNATIONAL MANUAL OF ONCOLOGY PRACTICE. 2019;p. 973-989
Superior Vena Cava Syndrome
Tolia M; Tsoukalas N; Zerdes I; Hajiioannou J; Kyrgias G
Book chapter: UTERINE CERVICAL CANCER. 2019;p. 191-214
Management of Recurrent Uterine Cervical Cancer
Zarkavelis G; Papadaki A; Kefas A; Zerdes I; Tatsi K; Boussios S
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2018;13(10):s563-s564
P1.09-36 Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC)
Tsoukalas N; Giaginis C; Alexandrou P; Tolia M; Binas I; Baxevanos P; Aravantinou E; Tsapakidis K; Galanopoulos M; Kiakou M; Zerdes I; Kostakis I; Litos I; Liontos M; Tsiambas E; Sfiniadakis I; Kyrgias G; Kavantzas N; Patsouris E; Theocharis S
Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2018;13(10):s563
P1.09-35 Clinical Impact of Systematic Inflammation and Histologic Grade in Non Small Cell Lung Carcinoma (NSCLC)
Tsoukalas N; Giaginis C; Tsapakidis K; Tolia M; Binas I; Aravantinou E; Baxevanos P; Galanopoulos M; Kiakou M; Zerdes I; Kostakis I; Nikolaou C; Litos I; Liontos M; Tsiambas E; Gioulbasanis I; Karameris A; Liaskonis K; Kyrgias G; Theocharis S
Review: ONCOGENE. 2018;37(34):4639-4661
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:e23088
Regulation of PD-L1 in breast cancer
Zerdes I; Tsesmetzis N; Lovrot J; Rolny C; Bergh JCS; Rassidakis G; Foukakis T
Review: FRONTIERS IN PHARMACOLOGY. 2017;8:247
The Role of Statins in Prevention of Preeclampsia: A Promise for the Future?
Katsi V; Georgountzos G; Kallistratos MS; Zerdes I; Makris T; Manolis AJ; Nihoyannopoulos P; Tousoulis D
Review: ANTICANCER RESEARCH. 2016;36(10):5031-5042
Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies.
Boussios S; Zarkavelis G; Seraj E; Zerdes I; Tatsi K; Pentheroudakis G
Editorial comment: BIOMARKERS IN MEDICINE. 2016;10(7):681-684
Intratumor heterogeneity: predicting and preventing therapeutic resistance.
Ziogas DE; Zerdes I; Lykoudis EG; Glantzounis G; Roukos DH
Editorial comment: FUTURE ONCOLOGY. 2016;12(9):1097-1100
Palbociclib: an approval at last for HER2-negative breast cancer.
Zerdes I; Ziogas DE; Lykoudis EG; Roukos DH
Review: RECENT PATENTS ON CARDIOVASCULAR DRUG DISCOVERY. 2015;9(2):63-72
Anti-VEGF Anticancer Drugs: Mind the Hypertension.
Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
Visa fler

Anställningar

Anknuten till Forskning (postdoktor), Onkologi-Patologi, Karolinska Institutet, 2020-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2020
MD, Medical School, University of Ioannina, 2015

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI